In Re Brand Name Prescription Drugs Antitrust Litigation
Author :
Publisher :
Page : 160 pages
File Size : 31,6 MB
Release : 1997
Category :
ISBN :
Author :
Publisher :
Page : 160 pages
File Size : 31,6 MB
Release : 1997
Category :
ISBN :
Author :
Publisher : DIANE Publishing
Page : 129 pages
File Size : 42,97 MB
Release : 2002
Category :
ISBN : 1428951938
Author :
Publisher : U.S. Government Printing Office
Page : 94 pages
File Size : 21,87 MB
Release : 1998
Category : Business & Economics
ISBN :
Author :
Publisher :
Page : 62 pages
File Size : 38,52 MB
Release : 1985
Category :
ISBN :
Author : Roy Levy
Publisher : DIANE Publishing
Page : 226 pages
File Size : 37,76 MB
Release : 1999
Category : Antitrust law
ISBN : 1428953639
Author : Aspen Health Law Center
Publisher : Jones & Bartlett Learning
Page : 158 pages
File Size : 10,89 MB
Release : 1998
Category : Antitrust law
ISBN : 9780834212275
Antitrust laws touch upon a wide range of conduct and business relationships in the delivery of health care services, and the issues that should be of concern to health care organizations are described. Health Care Antitrust provides practical overviews of the principal legal issues relating to health care antitrust, as well as a general understanding of antitrust analysis as applied to contractual relationships and business strategies that present antitrust risks in a managed care environment.
Author : Robin Feldman
Publisher : Cambridge University Press
Page : 165 pages
File Size : 50,60 MB
Release : 2017-06-09
Category : Law
ISBN : 131673949X
While the shockingly high prices of prescription drugs continue to dominate the news, the strategies used by pharmaceutical companies to prevent generic competition are poorly understood, even by the lawmakers responsible for regulating them. In this groundbreaking work, Robin Feldman and Evan Frondorf illuminate the inner workings of the pharmaceutical market and show how drug companies twist health policy to achieve goals contrary to the public interest. In highly engaging prose, they offer specific examples of how generic competition has been stifled for years, with costs climbing into the billions and everyday consumers paying the price. Drug Wars is a guide to the current landscape, a roadmap for reform, and a warning of what is to come. It should be read by policymakers, academics, patients, and anyone else concerned with the soaring costs of prescription drugs.
Author : Robin Feldman
Publisher : Cambridge University Press
Page : 201 pages
File Size : 13,37 MB
Release : 2019-04-11
Category : Law
ISBN : 1108659500
In the warped world of prescription drug pricing, generic drugs can cost more than branded ones, old drugs can be relaunched at astronomical prices, and low-cost options are shut out of the market. In Drugs, Money and Secret Handshakes, Robin Feldman shines a light into the dark corners of the pharmaceutical industry to expose a web of shadowy deals in which higher-priced drugs receive favorable treatment and patients are channeled toward the most expensive medicines. At the center of this web are the highly secretive middle players who establish coverage levels for patients and negotiate with drug companies. By offering lucrative payments to these middle players (as well as to doctors and hospitals), drug companies ensure that inexpensive drugs never gain traction. This system of perverse incentives has delivered the kind of exorbitant drug prices - and profits - that everyone loves except for those who pay the bills.
Author : National Academies of Sciences, Engineering, and Medicine
Publisher : National Academies Press
Page : 235 pages
File Size : 12,3 MB
Release : 2018-03-01
Category : Medical
ISBN : 0309468086
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author :
Publisher :
Page : 80 pages
File Size : 34,22 MB
Release : 1982
Category :
ISBN :